|
1
|
Fallon M, Giusti R, Aielli F, Hoskin P,
Rolke R, Sharma M and Ripamonti C; ESMO Guidelines Committee, :
Management of cancer pain in adult patients: ESMO clinical practice
guidelines. Ann Oncol. 29 (Suppl 4):iv166–iv191. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Swarm RA and Dans M: NCCN frameworks for
resource stratification of nccn guidelines: Adult cancer pain and
palliative care. J Natl Compr Canc Netw. 16:628–631. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Caraceni A, Hanks G, Kaasa S, Bennett MI,
Brunelli C, Cherny N, Dale O, De Conno F, Fallon M, Hanna M, et al:
Use of opioid analgesics in the treatment of cancer pain:
Evidence-based recommendations from the EAPC. Lancet Oncol.
13:e58–e68. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Owusu Obeng A, Hamadeh I and Smith M:
Review of opioid pharmacogenetics and considerations for pain
management. Pharmacotherapy. 37:1105–1121. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Coluzzi F, Caputi FF, Billeci D, Pastore
AL, Candeletti S, Rocco M and Romualdi P: Safe use of opioids in
chronic kidney disease and hemodialysis patients: Tips and tricks
for non-pain specialists. Ther Clin Risk Manag. 16:821–837. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kalso E and Vainio A: Morphine and
oxycodone hydrochloride in the management of cancer pain. Clin
Pharmacol Ther. 47:639–646. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Watson CPN, Moulin D, Watt-Watson J,
Gordon A and Eisenhoffer J: Controlled-release oxycodone relieves
neuropathic pain: A randomized controlled trial in painful diabetic
neuropathy. Pain. 105:71–78. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bell GC, Donovan KA and McLeod HL:
Clinical implications of opioid pharmacogenomics in patients with
cancer. Cancer Control. 22:426–432. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rakvåg TT, Klepstad P, Baar C, Kvam TM,
Dale O, Kaasa S, Krokan HE and Skorpen F: The Val158Met
polymorphism of the human catechol-O-methyltransferase (COMT) gene
may influence morphine requirements in cancer pain patients. Pain.
116:73–78. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rakvåg TT, Ross JR, Sato H, Skorpen F,
Kaasa S and Klepstad P: Genetic variation in the
catechol-O-methyltransferase (COMT) gene and morphine requirements
in cancer patients with pain. Mol Pain. 4:642008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Reyes-Gibby CC, Shete S, Rakvåg T, Bhat
SV, Skorpen F, Bruera E, Kaasa S and Klepstad P: Exploring joint
effects of genes and the clinical efficacy of morphine for cancer
pain: OPRM1 and COMT gene. Pain. 130:25–30. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Matsuoka H, Tsurutani J, Chiba Y, Fujita
Y, Sakai K, Yoshida T, Nakura M, Sakamoto R, Makimura C, Ohtake Y,
et al: Morphine versus oxycodone for cancer pain using a
catechol-O-methyltransferase genotype biomarker: A multicenter,
randomized, open-label, phase III clinical trial (RELIEF Study).
Oncologist. 28:278–e166. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Crews KR, Monte AA, Huddart R, Caudle KE,
Kharasch ED, Gaedigk A, Dunnenberger HM, Leeder JS, Callaghan JT,
Samer CF, et al: Clinical pharmacogenetics implementation
consortium guideline for CYP2D6, OPRM1, and COMT genotypes and
select opioid therapy. Clin Pharmacol Ther. 110:888–896. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Matsuoka H, Arao T, Makimura C, Takeda M,
Kiyota H, Tsurutani J, Fujita Y, Matsumoto K, Kimura H, Otsuka M,
et al: Expression changes in arrestin β 1 and genetic variation in
catechol-O-methyltransferase are biomarkers for the response to
morphine treatment in cancer patients. Oncol Rep. 27:1393–1399.
2012.PubMed/NCBI
|
|
15
|
Matsuoka H, Yoshiuchi K, Koyama A,
Makimura C, Fujita Y, Tsurutani J, Sakai K, Sakamoto R, Nishio K
and Nakagawa K: Expectation of a decrease in pain affects the
prognosis of pain in cancer patients: A prospective cohort study of
response to morphine. Int J Behav Med. 24:535–541. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Matsuoka H, Makimura C, Koyama A, Fujita
Y, Tsurutani J, Sakai K, Sakamoto R, Nishio K and Nakagawa K:
Prospective replication study implicates the
catechol-O-methyltransferase Val158Met polymorphism as a
biomarker for the response to morphine in patients with cancer.
Biomed Rep. 7:380–384. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Swarm R, Abernethy AP, Anghelescu DL,
Benedetti C, Blinderman CD, Boston B, Cleeland C, Coyle N,
Deleon–Casasola OA, Eilers JG, et al: Adult cancer pain. J Natl
Compr Canc Netw. 8:1046–1086. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Agúndez JAG, Luengo A, Herráez O, Martínez
C, Alonso-Navarro H, Jiménez-Jiménez FJ and García-Martín E:
Nonsynonymous polymorphisms of histamine-metabolising enzymes in
patients with Parkinson's disease. Neuromolecular Med. 10:10–16.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cook-Sather SD, Li J, Goebel TK, Sussman
EM, Rehman MA and Hakonarson H: TAOK3, a novel genome-wide
association study locus associated with morphine requirement and
postoperative pain in a retrospective pediatric day surgery
population. Pain. 155:1773–1783. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Foulkes T and Wood JN: Pain genes. PLoS
Genet. 4:e10000862008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ji RR, Berta T and Nedergaard M: Glia and
pain: Is chronic pain a gliopathy? Pain. 154 (Suppl 1):S10–S28.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ramesh G, MacLean AG and Philipp MT:
Cytokines and chemokines at the crossroads of neuroinflammation,
neurodegeneration, and neuropathic pain. Mediators Inflamm.
2013:4807392013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Russo R, D'Agostino G, Raso GM, Avagliano
C, Cristiano C, Meli R and Calignano A: Central administration of
oxytocin reduces hyperalgesia in mice: Implication for cannabinoid
and opioid systems. Peptides. 38:81–88. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sousa-Valente J, Andreou AP, Urban L and
Nagy I: Transient receptor potential ion channels in primary
sensory neurons as targets for novel analgesics. Br J Pharmacol.
171:2508–2527. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang Z, Feng J, Mao A, Le K, La Placa D,
Wu X, Longmate J, Marek C, St Amand RP, Neuhausen SL and Shively
JE: SNPs in inflammatory genes CCL11, CCL4 and MEFV in a
fibromyalgia family study. PLoS One. 13:e01986252018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Světlík S, Hronová K, Bakhouche H,
Matoušková O and Slanař O: Pharmacogenetics of chronic pain and its
treatment. Mediators Inflamm. 2013:8643192013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gabriel S, Ziaugra L and Tabbaa D: SNP
genotyping using the sequenom MassARRAY iPLEX platform. Curr Protoc
Hum Genet. Chapter 2: Unit 2.12. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Matic M, de Wildt SN, Tibboel D and van
Schaik RHN: Analgesia and opioids: A pharmacogenetics shortlist for
implementation in clinical practice. Clin Chem. 63:1204–1213. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shiotani A, Murao T, Fujita Y, Fujimura Y,
Sakakibara T, Nishio K and Haruma K: Novel single nucleotide
polymorphism markers for low dose aspirin-associated small bowel
bleeding. PLoS One. 8:e842442013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Matsuoka H, Tsurutani J, Chiba Y, Fujita
Y, Terashima M, Yoshida T, Sakai K, Otake Y, Koyama A, Nishio K and
Nakagawa K: Selection of opioids for cancer-related pain using a
biomarker: A randomized, multi-institutional, open-label trial
(RELIEF study). BMC Cancer. 17:6742017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nakamura A, Hasegawa M, Minami K, Kanbara
T, Tomii T, Nishiyori A, Narita M, Suzuki T and Kato A:
Differential activation of the µ-opioid receptor by oxycodone and
morphine in pain-related brain regions in a bone cancer pain model.
Br J Pharmacol. 168:375–388. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nielsen CK, Ross FB, Lotfipour S, Saini
KS, Edwards SR and Smith MT: Oxycodone and morphine have distinctly
different pharmacological profiles: Radioligand binding and
behavioural studies in two rat models of neuropathic pain. Pain.
132:289–300. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Klepstad P, Fladvad T, Skorpen F, Bjordal
K, Caraceni A, Dale O, Davies A, Kloke M, Lundström S, Maltoni M,
et al: Influence from genetic variability on opioid use for cancer
pain: A European genetic association study of 2294 cancer pain
patients. Pain. 152:1139–1145. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chang HS, Kim JS, Lee JH, Cho JI, Rhim TY,
Uh ST, Park BL, Chung IY, Park CS and Shin HD: A single nucleotide
polymorphism on the promoter of eotaxin1 associates with its mRNA
expression and asthma phenotypes. J Immunol. 174:1525–1531. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liang C, Ni G, Ma J, Liu H, Mao Z, Sun H
and Zhang X: Impact of tag single nucleotide polymorphisms (SNPs)
in CCL11 gene on risk of subtypes of ischemic stroke in xinjiang
han populations. Med Sci Monit. 23:4291–4298. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kang WS, Kim YJ, Park HJ, Kim SK, Paik JW
and Kim JW: Association of CCL11 promoter polymorphisms with
schizophrenia in a Korean population. Gene. 656:80–85. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pawlik K, Piotrowska A, Kwiatkowski K,
Ciapała K, Popiolek-Barczyk K, Makuch W and Mika J: The blockade of
CC chemokine receptor type 1 influences the level of nociceptive
factors and enhances opioid analgesic potency in a rat model of
neuropathic pain. Immunology. 159:413–428. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pawlik K, Ciechanowska A, Ciapała K,
Rojewska E, Makuch W and Mika J: Blockade of CC chemokine receptor
type 3 diminishes pain and enhances opioid analgesic potency in a
model of neuropathic pain. Front Immunol. 12:7813102021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lovo EE, Moreira A, Cruz C, Carvajal G,
Barahona KC, Caceros V, Blanco A, Mejias R, Alho E and Soto T:
Radiomodulation in mixed, complex cancer pain by triple target
irradiation in the brain: A preliminary experience. Cureus.
14:e254302022.PubMed/NCBI
|
|
40
|
Richards GC, Lluka LJ, Smith MT, Haslam C,
Moore B, O'Callaghan J and Strong J: Effects of long-term opioid
analgesics on cognitive performance and plasma cytokine
concentrations in patients with chronic low back pain: A
cross-sectional pilot study. Pain Rep. 3:e6692018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhou TQ, Gao HY, Guan XH, Yuan X, Fang GG,
Chen Y and Ye DW: Chemokines and their receptors: Potential
therapeutic targets for bone cancer pain. Curr Pharm Des.
21:5029–5033. 2015. View Article : Google Scholar : PubMed/NCBI
|
